Surrey Heartlands

Joint Formulary & PAD

Alfuzosin hydrochloride - Benign prostatic hyperplasia

You are here : Home > Formulary Search > Alfuzosin hydrochloride - Benign prostatic hyperplasia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Modified release tablets
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important
2nd or 3rd line. Tamsulosin MR capsules or Doxazosin immediate release tablets are preferred

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Alfuzosin hydrochloride
Indication :
Benign prostatic hyperplasia
Group Name :
Keywords :
BPH, LUTS, urinary tract symptoms, urinary frequency, urinary retention
Brand Names Include :
Xatral, Vasran, Zochek, Besavar
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Alfuzosin hydrochloride is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Benign prostatic hyperplasia.

Committee Recommendations (1)

06 Dec 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Where an alpha blocker is indicated, the PCN recommend one of the following as a 1st-line treatment option

  • Tamsulosin (modified release) – GREEN (NOTE - prescribe as generic capsules)
  • Doxazosin (immediate release) – GREEN (NOTE - XL / modified release preparations are considered BLACK)

Alfuzosin is more costly and is therefore not recommended as a 1st-line option. (NOTE - prescribe generically).

Terazosin is reserved for patients with hepatic or renal failure since no dose adjustment is required in these patient groups